{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-268043","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.064247+00:00","generated_at":"2026-05-16T23:45:34.940096+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amylyx Q3 net loss narrows to $34.4M; cash $344M after $191M offering","bullets":["Net loss $34.4M ($0.37/sh) vs $72.7M ($1.07/sh) in Q3 2024; R&D $19.9M, SG&A $16.2M.","Cash and securities $344M at Sept 30, up from $180.8M at June 30; cash runway into 2028.","Phase 3 LUCIDITY trial of avexitide recruitment completion expected Q1 2026; topline data Q3 2026.","Phase 1 LUMINA trial of AMX0114 in ALS fully enrolled cohort 1; early data at Dec symposium.","Plan to initiate Phase 3 trial of AMX0035 in Wolfram syndrome H2 2026 pending FDA alignment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-268043","json":"https://secwatch.observer/filing/0001193125-25-268043.json","markdown":"https://secwatch.observer/filing/0001193125-25-268043.md","text":"https://secwatch.observer/filing/0001193125-25-268043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000119312525268043/0001193125-25-268043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000119312525268043/amlx-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:45:34.940096+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}